Carl-von-Basedow-Klinikum Saalekreis gGmbH
- Address
- lock Available on a paid plan
Neurology and Stroke Research
At Carl-von-Basedow-Klinikum Saalekreis gGmbH in Merseburg, clinical research in nervous system diseases focuses on serious emergency conditions such as acute ischemic stroke and status epilepticus in older adults. These studies are designed to evaluate new treatment options and generate evidence for better care in time-critical neurological conditions.
- Testing a new therapy for acute ischemic stroke to assess safety and potential benefit
- Studying treatment effectiveness for established status epilepticus in people aged 65 and older
This work aims to improve outcomes in high-risk neurological emergencies through better treatment strategies and clinical evidence.
Oncology Research
Clinical trials in neoplasms at this hospital are centered on difficult-to-treat cancers, especially advanced colorectal carcinoma. The research is evaluating whether adding a new supportive treatment approach can improve disease control and help patients whose cancer no longer responds well to standard therapy.
- Assessing treatment effectiveness in metastatic colorectal carcinoma
- Exploring a new combination approach to improve tumor control in chemotherapy-resistant disease
The Medizinische Klinik II contributes to studies that aim to refine cancer care for patients with advanced disease.
Hematology and Rare Disease Studies
Research also includes polycythemia vera, a chronic blood disorder within the broader area of neoplasms. One study is focused on identifying patients at risk of hydroxyurea resistance or intolerance, using predictive factors to support more personalized treatment decisions.
- Evaluating hydroxyurea resistance in polycythemia vera
- Using predictive tools to improve treatment planning for patients starting regular therapy
This line of research reflects an effort to improve long-term management of a complex hematologic condition through earlier identification of treatment challenges.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Universitaet Leipzig1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Carl-von-Basedow-Klinikum Saalekreis gGmbH
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| BRIGHT - A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS) | Lumosa Therapeutics Co. Ltd. | Phase II | Not Recruiting | Dec 2023 | May 2025 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 1 | Unknown | 2025-02-25 | 2025-02-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
